{"id":"mk-0518","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Elevated creatine kinase"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL5992860","moleculeType":null,"molecularWeight":"426.25"},"_fixedAt":"2026-03-30T17:54:43.520046","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting HIV integrase, MK-0518 (raltegravir) prevents the integration of viral DNA into the host genome, a critical step in HIV replication. This mechanism allows the drug to suppress viral replication and reduce HIV RNA levels in infected individuals. It represents a novel class of antiretroviral agents distinct from reverse transcriptase and protease inhibitors.","oneSentence":"MK-0518 is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:33.050Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"HIV-1 infection in combination antiretroviral therapy"}]},"_fixedFields":["sideEffects","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT04024150","phase":"","title":"Pregnancy, Anti-integrase and Lymphocyte Repertoire of the Newborn","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-04","conditions":"Anti-integrases","enrollment":29},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT05642481","phase":"","title":"Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT02140255","phase":"PHASE1, PHASE2","title":"Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-23","conditions":"HIV Infection","enrollment":1120},{"nctId":"NCT03194165","phase":"","title":"Population Pharmacokinetics of Antiretroviral in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-16","conditions":"Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed","enrollment":65},{"nctId":"NCT01234116","phase":"PHASE4","title":"Post-Exposure Prophylaxis in Health Care Workers","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2011-02","conditions":"Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT03311945","phase":"PHASE3","title":"Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2018-05-02","conditions":"HIV Infections, HIV-1-infection, HIV Seropositivity","enrollment":33},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT01513122","phase":"PHASE4","title":"Bone and Body Comp: A Sub Study of the SECOND-LINE Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2010-02","conditions":"HIV","enrollment":210},{"nctId":"NCT03029689","phase":"PHASE3","title":"Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2017-07-28","conditions":"HIV","enrollment":61},{"nctId":"NCT03333083","phase":"PHASE3","title":"Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen","status":"TERMINATED","sponsor":"Judit Pich","startDate":"2018-05-03","conditions":"HIV Seropositivity, HIV Infections, HIV-1-infection","enrollment":17},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT04513626","phase":"PHASE2","title":"HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label","status":"RECRUITING","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2020-09-15","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT02691065","phase":"PHASE4","title":"Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2017-01-20","conditions":"HIV","enrollment":6},{"nctId":"NCT01854762","phase":"PHASE2, PHASE3","title":"Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection","status":"TERMINATED","sponsor":"Fundação Bahiana de Infectologia","startDate":"2015-06-01","conditions":"HIV, Pregnancy","enrollment":33},{"nctId":"NCT01059422","phase":"PHASE4","title":"Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients","status":"COMPLETED","sponsor":"Central Institute of Epidemiology, Moscow, Russia","startDate":"2010-10","conditions":"HIV Infections, Tuberculosis","enrollment":10},{"nctId":"NCT03174977","phase":"EARLY_PHASE1","title":"Pharmacokinetics Distribution of Raltegravir by PET/MR","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2018-04-01","conditions":"HIV-1-infection","enrollment":10},{"nctId":"NCT01480713","phase":"PHASE3","title":"Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2012-05","conditions":"HIV-1 Infection","enrollment":41},{"nctId":"NCT01712425","phase":"PHASE1","title":"Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2012-10","conditions":"HIV","enrollment":48},{"nctId":"NCT01251601","phase":"","title":"The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-11","conditions":"HIV, Pregnancy","enrollment":""},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT02708342","phase":"","title":"Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2016-04","conditions":"HIV","enrollment":100},{"nctId":"NCT04258475","phase":"PHASE4","title":"The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2020-12-09","conditions":"Calcium Supplementation in HIV Patients Using Raltegravir","enrollment":12},{"nctId":"NCT02336074","phase":"PHASE2","title":"Research In Viral Eradication of HIV Reservoirs","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-11-27","conditions":"HIV","enrollment":60},{"nctId":"NCT02210715","phase":"PHASE4","title":"Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-03","conditions":"HIV, Fatty Liver, Nonalcoholic Steatohepatitis","enrollment":31},{"nctId":"NCT04460924","phase":"","title":"ARTiBIOME: Observational Study on the Effect of HIV and ART on Gut Microbiome","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2020-11-01","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT05648201","phase":"PHASE4","title":"Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"Hiv","enrollment":36},{"nctId":"NCT01867320","phase":"EARLY_PHASE1","title":"Raltegravir for HAM/TSP","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2013-09-05","conditions":"HTLV-I Infection","enrollment":19},{"nctId":"NCT05751031","phase":"","title":"Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)","status":"UNKNOWN","sponsor":"Fondazione Penta UK","startDate":"2023-02-20","conditions":"HIV Infections","enrollment":1200},{"nctId":"NCT03332095","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT03579485","phase":"","title":"An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients.(RalAge)","status":"UNKNOWN","sponsor":"Azienda Policlinico Umberto I","startDate":"2018-01-31","conditions":"Hiv","enrollment":90},{"nctId":"NCT01204905","phase":"NA","title":"R5 Integrase Study in HIV-1 Naive Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-09","conditions":"HIV Infections","enrollment":7},{"nctId":"NCT00594646","phase":"PHASE4","title":"HIV Non Occupational Post-Exposure Prophylaxis (PEP)","status":"COMPLETED","sponsor":"Fenway Community Health","startDate":"2008-02","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT04901728","phase":"","title":"Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)","status":"UNKNOWN","sponsor":"University of Sussex","startDate":"2021-07-01","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT01231516","phase":"PHASE3","title":"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-26","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":724},{"nctId":"NCT04887675","phase":"NA","title":"Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI","status":"UNKNOWN","sponsor":"University of Novi Sad","startDate":"2021-05-01","conditions":"HIV I Infection, HIV Associated Lipodystrophy, Metabolic Syndrome","enrollment":120},{"nctId":"NCT01828073","phase":"","title":"Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-05-19","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01780831","phase":"PHASE1","title":"Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-28","conditions":"HIV Infections","enrollment":52},{"nctId":"NCT01751568","phase":"PHASE1, PHASE2","title":"Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-11-12","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT00515827","phase":"PHASE2","title":"Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00537394","phase":"PHASE3","title":"Optimizing Treatment for Treatment-Experienced, HIV-Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-01","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT00485264","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-09-17","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT00660972","phase":"PHASE1","title":"Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00852618","phase":"","title":"Intensive Viral Dynamics Substudy of A5248","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Treatment Naive","enrollment":11},{"nctId":"NCT01896921","phase":"PHASE3","title":"Switch to Maraviroc + Integrase Inhibitor","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2013-09","conditions":"HIV","enrollment":7},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03374358","phase":"PHASE4","title":"Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2018-01-10","conditions":"HIV Seropositivity, Metabolic Syndrome, Fatty Liver","enrollment":45},{"nctId":"NCT01147107","phase":"PHASE4","title":"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2014-02","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":80},{"nctId":"NCT04051970","phase":"PHASE3","title":"Reducing Antiretroviral Treatments","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2019-11-27","conditions":"HIV-1-infection","enrollment":360},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT01939197","phase":"PHASE2, PHASE3","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-08-30","conditions":"Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C","enrollment":318},{"nctId":"NCT02611895","phase":"NA","title":"Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-03","conditions":"HIV-1 Infection","enrollment":120},{"nctId":"NCT02212379","phase":"PHASE2","title":"Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-01","conditions":"HIV-1 Infection","enrollment":170},{"nctId":"NCT03060447","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-05-09","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT03205566","phase":"PHASE4","title":"Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2017-09-19","conditions":"Hiv","enrollment":38},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT00738569","phase":"NA","title":"Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2008-07","conditions":"HIV","enrollment":30},{"nctId":"NCT01288417","phase":"PHASE1","title":"Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2011-08","conditions":"HIV Infections, HCV Infections","enrollment":24},{"nctId":"NCT01246804","phase":"PHASE1","title":"The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-11","conditions":"HIV Infections, Depression, Mild Cognitive Impairment","enrollment":18},{"nctId":"NCT00943540","phase":"PHASE2","title":"Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-07","conditions":"HIV Infection, HIV Infections","enrollment":20},{"nctId":"NCT02577042","phase":"PHASE4","title":"Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2015-10-15","conditions":"Aging-related Inflammation in HIV-infected Patients","enrollment":42},{"nctId":"NCT01779687","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-03","conditions":"HIV, Hypercholesterolaemia","enrollment":24},{"nctId":"NCT00618241","phase":"PHASE1","title":"Pharmacokinetic Study on Raltegravir and Lamotrigine","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-02","conditions":"HIV Infection","enrollment":24},{"nctId":"NCT00665717","phase":"PHASE1","title":"The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-05","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01978782","phase":"PHASE1","title":"Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2014-01","conditions":"HIV, Depression","enrollment":24},{"nctId":"NCT00631449","phase":"PHASE4","title":"Raltegravir Intensification in HIV-infected Patients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-02","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT01159132","phase":"PHASE2","title":"Pharmacokinetics of Low Dose Raltegravir","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT01025427","phase":"PHASE4","title":"HIV Persistence and Viral Reservoirs","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-12","conditions":"HIV, HIV Infections","enrollment":16},{"nctId":"NCT03369743","phase":"","title":"Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD)","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2018-01-02","conditions":"HIV Infections","enrollment":125},{"nctId":"NCT03195452","phase":"PHASE2","title":"QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2017-11-08","conditions":"Virus-HIV","enrollment":100},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02858401","phase":"PHASE1","title":"Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-29","conditions":"HIV-1 Infection","enrollment":48},{"nctId":"NCT02995824","phase":"","title":"Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2002-01","conditions":"Liver Transplantation, HIV Infections, Antiretroviral Therapy","enrollment":271},{"nctId":"NCT00808002","phase":"PHASE3","title":"Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-02","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01618305","phase":"PHASE4","title":"Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission","status":"COMPLETED","sponsor":"Westat","startDate":"2013-09-05","conditions":"HIV Infections","enrollment":408},{"nctId":"NCT00995241","phase":"PHASE4","title":"Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2009-11","conditions":"HIV Infections","enrollment":5},{"nctId":"NCT00718536","phase":"PHASE4","title":"Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-08","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00685191","phase":"PHASE4","title":"HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2008-06","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT00554398","phase":"PHASE3","title":"Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2007-11","conditions":"HIV Infections","enrollment":69},{"nctId":"NCT01078233","phase":"","title":"Observational Data Analysis in EuroSIDA (MK-0518-058)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05-05","conditions":"HIV-1 Infections","enrollment":6617},{"nctId":"NCT01335620","phase":"PHASE4","title":"The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-04","conditions":"HIV","enrollment":19},{"nctId":"NCT01293123","phase":"NA","title":"Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2011-12","conditions":"HIV","enrollment":2},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT00982553","phase":"PHASE1","title":"The Raltegravir and Ribavirin Pharmacokinetics (PK) Study","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2009-09","conditions":"HIV Infections","enrollment":14}],"_emaApprovals":[],"_faersSignals":[{"count":9,"reaction":"DIARRHOEA"},{"count":8,"reaction":"PYREXIA"},{"count":8,"reaction":"RENAL FAILURE ACUTE"},{"count":7,"reaction":"BLOOD ALKALINE PHOSPHATASE INCREASED"},{"count":6,"reaction":"ANAEMIA"},{"count":6,"reaction":"NAUSEA"},{"count":6,"reaction":"VOMITING"},{"count":5,"reaction":"ADRENAL INSUFFICIENCY"},{"count":5,"reaction":"DEHYDRATION"},{"count":5,"reaction":"DRUG HYPERSENSITIVITY"}],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["raltegravir","Isentress®"],"phase":"phase_3","status":"active","brandName":"MK-0518","genericName":"MK-0518","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-0518 is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection in combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}